Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy
| Autor: | David Huggar, Russell L Knoth, Ronda Copher, Zhun Cao, Craig Lipkin, Ali McBride, Thomas W LeBlanc |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Future Oncology. 18:3609-3621 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2022-0706 |
| Popis: | Aim: This retrospective, observational study assessed healthcare resource utilization (HCRU) and costs for newly diagnosed acute myeloid leukemia (AML) patients receiving intensive induction chemotherapy. Materials & methods: Adult AML patients with inpatient hospitalization or hospital-based outpatient visit receiving intensive induction chemotherapy (CPX-351 or 7 + 3 treatments) were identified from the Premier Healthcare Database (US). Results: All 642 patients had inpatient hospitalizations (median number = 2; median length of stay = 16 days); 22.4% had an ICU admission. Median total outpatient hospital cost was US$2904 per patient, inpatient hospital cost was $83,440 per patient, and ICU cost was $16,550 per patient. Discussion: In the US hospital setting, substantial HCRU and costs associated with intensive induction chemotherapy for AML were driven by inpatient hospitalizations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|